Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, multicenter Phase 3 study evaluating the performance of
the Albuterol Spiromax dose counter in patients with a diagnosis of asthma and/or COPD. The
purpose of this study is to evaluate the functionality, reliability, and accuracy of the
Albuterol Spiromax inhaler integrated dose counter in a clinical setting.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries